Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 458

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 5
Chunk 458
---
 Director and Head of Protein Science
at Ventus Therapeutics, Waltham, MA, a clinical-stage biopharmaceutical company deploying leading-edge structural biology and unique computational
chemistry tools to develop a robust pipeline of novel medicines in immunology, inflammation, and neurology. Dr. Prasad has raised
nearly $10 million in non-dilutive funding from NIH and Michael J Fox Foundation for Parkinson’s Research. Dr. Prasad
is a co-inventor on thirteen U.S./International issued patents and published 45 peer-reviewed research articles and textbook chapters.
He also serves on the editorial boards of Organic & Medicinal Chemistry International Journal and Chemical Sciences Journal,
Omics Publications. Dr. Prasad received his Ph.D. in Biophysics from the Indian Institute of Science, Bangalore, and completed postdoctoral
training at the University of Minnesota and the Scripps Research Institute, La Jolla, California.

Myron W. Shulgan KC has served as
a member of our board of directors since January 2025. Mr. Shulgan is a lawyer who has over 40 years of trial experience.
He was a partner at Strosberg Sasso Sutts LLP from 2015 to 2024. Early in his career he worked as a federally appointed drug prosecutor
for three years where he prosecuted individuals charged with drug related offences. During this period he developed his trial skills.
Since then he has developed a trial practice during which he has represented corporations and individuals involved in complex commercial
litigation, construction claims, banking disputes and other business related matters in trials and appeals in all levels of Courts in
Canada including the Supreme Court of Canada. Mr. Shulgan has acted for and counselled clients in the manner in which they could
navigate the maze of laws in highly regulated businesses to assist them in achieving their goals to ensure that they comply with their
government mandated obligations. Mr. Shulgan received a bachelor of arts degree in political science and a bachelor of law degree
from the University of Windsor.

On January 27, 2025, Bright Green Corp. (“BGXX”) entered
into a Restructuring Support Agreement (the “RSA”) with Lynn Stockwell, BGXX’s CEO, Chair of the Board and majority
shareholder and the Company’s Chief Executive Officer and Executive Chair of the Board, reflecting an agreement to implement a prepackaged
restructuring of BGXX through the commencement of voluntary